Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis

PHASE3CompletedINTERVENTIONAL
Enrollment

451

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions
Esophagitis, RefluxEsophagitis, Peptic
Interventions
DRUG

Dexlansoprazole MR

Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.

DRUG

Dexlansoprazole MR

Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.

DRUG

Placebo

Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.

Trial Locations (96)

Unknown

Alabaster

Birmingham

Huntsville

Phoenix

Scottsdale

Tucson

Anaheim

Chula Vista

Fullerton

Garden Grove

Irvine

Lancaster

Long Beach

Los Angeles

Mission Hills

Palm Springs

Redwood City

San Diego

San Luis Obispo

Boulder

Colorado Springs

Lone Tree

Wheat Ridge

Waterbury

Boynton Beach

Jacksonville

Jupiter

Kissimmee

Lakeland

New Port Richey

Atlanta

Honolulu

Arlington Heights

Chicago

Hines

Oak Park

Rockford

Clive

Dubuque

Newton

Shawnee Mission

Topeka

Metairie

Shreveport

Hollywood

Lutherville

Troy

Chaska

Jackson

Mexico

St Louis

Washington

Omaha

Pahrump

New Brunswick

Bingampton

Brooklyn

Great Neck

Rochester

Charlotte

Elkin

Greensboro

Hickory

Salisbury

Statesville

Winston-Salem

Cincinnati

Mayfield Heights

Warren

Oklahoma City

Portland

Beaver Falls

Duncansville

Lansdale

Bristol

Chattanooga

Hermitage

Nashville

Austin

Beaumont

Bedford

Bryan

Corsicana

El Paso

Fort Worth

Houston

San Antonio

Bountiful

Ogden

Salt Lake City

West Jordan

Chesapeake

Danville

Spokane

Milwaukee

Monroe

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT00255164 - Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis | Biotech Hunter | Biotech Hunter